Company intelligence / Profile preview

Empress Therapeutics

Cambridge, Massachusetts, United Statesempresstx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

In less than two years, Empress has generated at least fifteen novel small molecules across multiple target classes and disease areas using its Chemilogics™ platform. The company expects to file multiple IND applications within the next two years. No clinical results have been reported yet as programs are preclinical[5].

Therapeutic areas: Other
Modalities: Small molecules
Industry: Biotech

Partnerships

Flagship Pioneering (funder/incubator)[1][3]

Beyond the preview

Go deeper on Empress Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Empress Therapeutics.

Explore the full profile